Next Generation Bio Innovation 2025

These advantages are more applicable to established, complex value chain ecosystems that are incorporating sustainable inputs or processes; bio-innovation isn’t just for start-ups and therapeutics, it is poised to become the backbone of industrial production. For bio-improved, bio-superior or bio-disruptive products in particular, achieving commercial viability can be more difficult due to higher upfront costs and scaling challenges. Bio-innovation can no longer rely on green premiums, and must be competitively priced, implying that production system approaches must be cost effective. Given the unique nature of these solutions, value chains and ecosystems must be positioned for adaptation, transformation or even complete creation through innovative production system approaches (such as decentralized production) to address demand with viable commercial models. In both cases, production system value is key to balancing the commercial viability equation. Commercial bio-innovation provides opportunities for businesses to become more resilient, flexible and versatile in how they source and operate; and to focus on reducing supply chain risk and lowering costs across the value chain. The time is now to reimagine how products and services are grown, sourced, processed, produced and delivered.Bio-innovation isn’t just for start-ups and therapeutics, it is poised to become the backbone of industrial production. Next Generation Bio-Innovation: Delivering Commercial Value 10